Back in 2016, a 6-year-old named Mila was diagnosed with Batten disease, a progressive and incurable genetic syndrome that would brutally strip away her sight and her ability to walk, and would cause dozens of seizures each day. The condition is fatal.
But her parents, Julia Vitarello and Alek Makovec, refused to lose hope. They contacted Dr. Tim Yu, a neurologist at Boston Children’s Hospital, who discovered the precise genetic mutation that caused her disease — and was able to devise an experimental treatment designed exclusively for Mila. His work is one of the first examples of therapies created for the benefit of a single patient — an “N of 1” study.
Mila’s bespoke therapy seems to have some effect — many of her symptoms were halted in their tracks.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect